Atebrioz (zilurgisertib)

Fibrodysplasia ossificans progressiva

Also known as INCB000928

Manufacturer: Mirum Pharmaceuticals
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in October 2026
Last updated: October 1, 2026

Section

Product information and disease description Place of product in therapy

Approaches to treatment

64 evidence topics · 22 sources

Current treatment options and standard of care37 evidence topics · 18 sources
Place in treatment, anticipated use, and care setting5 evidence topics · 5 sources
Heterogeneity of treatment effect5 evidence topics · 4 sources
Care management intervention strategies5 evidence topics · 4 sources
Other product development or post-marketing obligations required by the FDA3 evidence topics · 2 sources
Ongoing post-approval monitoring3 evidence topics · 5 sources
Expected outcomes of therapy6 evidence topics · 4 sources